Immunic Therapeutics

Immunic develops a clinical pipeline of orally administered small-molecule therapies for chronic inflammatory, autoimmune and neurologic diseases. Its lead program, vidofludimus calcium (IMU-838), is in phase 3 trials for relapsing multiple sclerosis, with top-line data expected by the end of 2026. Earlier-stage programs include IMU-381 and IMU-856.

The website names patients with multiple sclerosis and celiac disease as target populations. It does not describe commercial products or a revenue model. The company is listed on Nasdaq under the ticker IMUX.

Immunic, Inc. is headquartered in New York City, and its subsidiary Immunic AG in Gräfelfing near Munich conducts the research and development activities. Immunic AG was founded in 2016, and the group has operated under the name Immunic, Inc. since April 2019. The website lists 12 open roles across project management, medical, health economics, communications, pharmacovigilance, market access and HR, mainly in the US and in Gräfelfing.

Product: Oral small-molecule drug candidates; lead candidate vidofludimus calcium (IMU-838) is in phase 3 for relapsing multiple sclerosis.